Report Published: "Oman Pharmaceuticals & Healthcare Report Q4 2015"

Growth in Oman's pharmaceutical and healthcare market s will be driven by the roll out of medical insurance schemes and the completion of two medical cities , capitalising on the increased demand for healthcare services in both the domestic and international markets. Both projects are valued at over USD1bn each and will significantly improve the level of healthcare provision in Oman.

Headline Expenditure Projections

Pharmaceuticals: OMR203mn (USD528mn) in 2014 to OMR217mn (USD564mn) in 2015; 6.8% in local currency and US dollar terms. Forecast broadly in line with Q 2 15.
Healthcare: OMR853mn (USD2.22bn) in 2014 to OMR939mn (USD2.44bn) in 2015; +10.1% in local currency and US dollar terms. Forecast downgraded slightly from Q215.

Full Report Details at
- http://www.fastmr.com/prod/1047961_oman_pharmaceuticals.aspx?afid=301

Risk/Reward Index

Oman has limited longer-term commercial potential due to its small population and the fact that the government is responsible for the bulk of healthcare costs, which will increase the need for cost containment in the coming years. In Q315, Oman scores 49.0 out of 100 in the BMI Pharmaceutical Risk/Reward Index, which has seen the country maintain its position in 10th place in the Middle East and Africa matrix out of 31 countries.

Key Trends And Developments

Data from the insurance sector in June 2015 indicated that claims paid by companies rose during Q115 by 36% to reach OMR39mn (USD101mn). Health insurance accounted for 22% of total direct premiums.

The Ministry of Health launched the National Electronic Health Record System in May 2015. The system links a patient's files in affiliated health institutions so the patient can access their medical history at anytime from anywhere.

Two paediatric drugs Advil and Panadol (marketed by GlaxoSmithKline) were recalled by the Ministry of Health in May 2015 due to errors in the dosage advice in their leaflets.

The Oman Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Oman Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Oman pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Oman, to test other views - a key input for successful budgeting and strategic business planning in the Omani pharmaceutical and healthcare market.
* Target business opportunities and risks in the Omani pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Oman.
*

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Bahrain Pharmaceuticals & Healthcare Report Q4 2015
- Romania Pharmaceuticals & Healthcare Report Q4 2015
- Bulgaria Pharmaceuticals & Healthcare Report Q4 2015
- Peru Pharmaceuticals & Healthcare Report Q4 2015
- Latvia Pharmaceuticals & Healthcare Report Q4 2015